Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

Journal of Experimental Medicine

Volumn 191, Issue 10, 2000, Pages 1699-1708

  Klein, Christoph ^a,b   Bueler, Hansruedi ^a   Mulligan, Richard C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; B16F10; Gene therapy; Retrovirus; Tumor immunology

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; FEMALE; GENE THERAPY; GENE TRANSFER; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR CELL;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC ENGINEERING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM PROTEINS; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034658319     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.10.1699     Document Type: Article

References (50)

1. Dranoff, G., and R.C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58:417-454.
2. Schuler, G., and R.M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1183-1187.
3. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 57:503-512.
4. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713-716.
5. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:397-403.
6. Watanabe, Y., K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 86:9456-9460.
7. Teng, M.N., B.H. Park, H.K. Koeppen, K.J. Tracey, B.M. Fendly, and H. Schreiber. 1991. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. USA. 88: 3535-3539.
8. + T cell-dependent tumor rejection. J. Exp. Med. 174:1291-1298.
9. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long-lasting immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
10. Soiffer, R., T. Lynch, M. Mihm, K. Jung, C. Rhuda, J.C. Schmollinger, F.S. Hodi, L. Liebster, P. Lam, S. Mentzer, et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 95:13141-13146.
11. Celluzzi, C.M., J.I. Mayordomo, W.J. Storkus, M.T. Lotze, and L.D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
12. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
13. Paglia, P., C. Chiodoni, M. Rodolfo, and M.P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble-protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
14. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C. Celluzzi, L.D. Falo, C.J. Melief, S.T. Ildstad, W.M. Kast, A.B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302.
15. Fields, R.C., K. Shimizu, and J.J. Mule. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:9482-9487.
16. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558-561.
17. Boczkowski, D., S.K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465-472.
18. Ashley, D.M., B. Faiola, S. Nair, L.P. Hale, D.D. Bigner, and E. Gilboa. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1177-1182.
19. Song, W., H.L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M.A. Moore, and R.G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-1256.
20. Specht, J.M., G. Wang, M.T. Do, J.S. Lam, R.E. Royal, M.E. Reeves, S.A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically elective against established pulimonary metastases. J. Exp. Med. 186:1213-1221.
21. Bueler, H., and R.C. Mulligan. 1996. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol. Med. 2:545-555.
22. Lieschke, G.J., P.K. Rao, M.K. Gately, and R.C. Mulligan. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15:35-40.
23. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
24. Ory, D.S., B.A. Neugeboren, and R.C. Mulligan. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA. 93:11400-11406.
25. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M.L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
26. Chen, Y.T., E. Stockert, Y. Chen, P. Garin-Chesa, W.J. Rettig, P. van der Bruggen, T. Boon, and L.J. Old. 1994. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc. Natl. Acad. Sci. USA. 91: 1004-1008.
27. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643-1647.
28. Tahara, H., H.J. Zeh III, W.J. Storkus, I. Pappo, S.C. Watkins, U. Gubler, S.F. Wolf, P.D. Robbins, and M.T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182-189.
29. Zitvogel, L., H. Tahara, P.D. Robbins, W.J. Storkus, M.R. Clarke, M.A. Nalesnik, and M.T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155: 1393-1403.
30. Nanni, P., I. Rossi, C. De Giovanni, L. Landuzzi, G. Nicoletti, A. Stoppacciaro, M. Parenza, M.P. Colombo, and P.L. Lollini. 1998. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58:1225-1230.
31. van Elsas, A., A.A. Hurwitz, and J.P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355-366.
32. Brossart, P., A.W. Goldrath, E.A. Butz, S. Martin, and M.J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270-3276.
33. Timares, L., A. Takashima, and S.A. Johnston. 1998. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc. Natl. Acad. Sci. USA. 95:13147-13152.
34. Westermann, J., A. Aicher, Z. Qin, Z. Cayeux, K. Daemen, T. Blankenstein, B. Dorken, and A. Pezzutto. 1998. Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation. Gene. Ther. 5:264-271.
35. Cao, X., W. Zhang, L. He, Z. Xie, S. Ma, Q. Tao, Y. Yu, H. Hamada, and J. Wang. 1998. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161:6238-6244.
36. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
37. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389-400.
38. Rieser, C., G. Bock, H. Klocker, G. Bartsch, and M. Thurnber. 1997. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J. Exp. Med. 186:1603-1608.
39. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263-1272.
40. + hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J. Exp. Med. 185:341-349.
41. Brossart, P., F. Grunebach, G. Stuhler, V.L. Reichardt, R. Mohle, L. Kanz, and W. Brugger. 1998. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood. 92:4238-4247.
42. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747-752.
43. + T-helper and a T-killer cell. Nature. 393:474-478.
44. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478-480.
45. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
46. + T cells in vitro. Blood. 91:4652-4661.
47. Labeur, M.S., B. Roters, B. Pers, A. Mehling, T.A. Luger, T. Schwarz, and S. Grabbe. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:168-175.
48. Cumberbatch, M., R.J. Dearman, and I. Kimber. 1997. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology. 92:388-395.
49. Ludewig, B., D. Graf, H.R. Gelderblom, Y. Decker, R.A. Kroczek, and G. Pauli. 1995. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25:1943-1950.
50. Bjorck, P., J. Banchereau, and L. Flores-Romo. 1997. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int. Immunol. 9:365-372.